Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

Apr 15, 2019

SELL
$8.95 - $12.49 $96,293 - $134,379
-10,759 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$9.74 - $14.5 $104,792 - $156,005
10,759 New
10,759 $116,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.17B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Quantitative Systematic Strategies LLC Portfolio

Follow Quantitative Systematic Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.